FDA approves Casgevy CRISPR gene therapy for sickle cell disease November 8, 2025, marking first CRISPR treatment with 97% cure rate via one-time stem cell edit.
Vertex Pharmaceuticals and CRISPR Therapeutics’ $2.2 million treatment edits BCL11A gene, boosting fetal hemoglobin to prevent sickling in red blood cells.
Phase 3 trials show 94% of 31 patients free of vaso-occlusive crises for 12 months, 100% transfusion-free at 24 months.
Global launch planned for 2026, targeting $3 billion market, with 100,000 U.S. patients affected annually.
Editing process involves harvesting stem cells, CRISPR modification, chemotherapy conditioning, and reinfusion.
Long-term data from 44 patients show 96% severe crisis-free at 2 years, 91% transfusion-independent.
This approval’s quiet revolution unveils new era where CRISPR’s vast precision bridges genetic voids, transforming sickle cell with enduring harmony.
